GlassScriptPhysician profile
Randee B Kidder
NPI 1962820134
$30,306.15
in general payments reported to CMS, 2019-2025
22 companies · $3,797 in 2025
The $3,797 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $835 · 2022: $5,935 · 2023: $4,677 · 2024: $15K · 2025: $3,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,300 · Travel and Lodging: $1,167 · Consulting Fee: $600 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,359.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,300.00 |
| Travel and Lodging | $1,167.33 |
| Consulting Fee | $600.00 |
| Education | $109.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $14,589.64 | 2022-2025 | Omvoh, Zepbound |
| Abbvie INC. | $5,757.52 | 2021-2025 | |
| Janssen Biotech, INC. | $2,248.90 | 2021-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $1,889.22 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $1,389.39 | 2021-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $974.77 | 2022-2024 | Stelara, Tremfya |
| Daiichi Sankyo INC. | $783.98 | 2021-2025 | Injectafer |
| Pfizer INC. | $669.14 | 2021-2025 | |
| Madrigal Pharmaceuticals | $589.25 | 2024-2025 | Rezdiffra, Resmetirom |
| Celltrion USA INC. | $387.42 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Organon LLC | $219.96 | 2022-2025 | Hadlima |
| Bayer Healthcare Pharmaceuticals INC. | $139.29 | 2021 | |
| Pharmacosmos Therapeutics INC. | $135.13 | 2022-2025 | Monoferric |
| Ferring Pharmaceuticals INC. | $134.08 | 2023-2024 | Rebyota |
| Fresenius Kabi USA, LLC | $123.44 | 2023-2024 | Idacio |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.80 | 2023-2024 | Cyltezo |
| Aimmune Therapeutics, INC. | $42.32 | 2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.10 | 2024 | Trulance, Xifaxan |
| Sunovion Pharmaceuticals INC. | $22.15 | 2022 | |
| Merck Sharp & Dohme LLC | $20.74 | 2022 | |
| Exact Sciences Corporation | $19.44 | 2025 | The Cologuard Plus Collection Kit |
| Braintree Laboratories, INC. | $16.47 | 2024 | Suflave, Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randee Kidder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.